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PP-127 Transmission of hepatitis C between spouses
an epidemiological study at National Liver
Institute hospital
W.S. Morad*. Community Medicine, National Liver
Institute, Menouﬁya University, Egypt
Background and Aims: In Egypt, relatively higher rates of
sexual transmission have been reported and reﬂect the
higher background prevalence in this country. In rural Egypt,
sexual transmission between monogamous spouses ranged
between 3 and 34%. This is a cross sectional hospital based
study evaluated the non-sexual and sexual risk factors of
HCV infection transmission from male and female index
cases to their spouses, to assess proportionate morbidity
rate of HCV disease during the period of the study and
to assess the relationship between the degree of HCV
viremia in index male and female cases and transmission of
infection to their spouses. This study documented previously
uncertained life-style risk factors for HCV transmission
between spouses, conﬁrmed the high prevalence of HCV
infection (17% to 26%) in Egypt which is higher than
other parts of the world, and provided evidence of sexual
transmission of HCV.
Results: Proportionate morbidity rate (PMR) of HCV disease
in NLI during the period of the study was 80% and
HCV transmission from wife to husband including sexual
relationship occurred in 46% of cases while from husband to
wife was 25% and 35.5% overall HCV transmission between
spouses.
Conclusion: This study emphasizes that transmission
between spouses signiﬁcantly occur due to sexual contact
but we can’t ignore the signiﬁcant role of non sexual risk
factors of HCV transmission among married couples such
as type of occupation, sharing clippers or nail cutters and
blood transfusion and others.
PP-128 A ﬁve-year follow-up of ninety-nine hepatitis C
patients
C.-S. Lin1 *, L.-H. She1, J. Liu1, Z.-X. Zhao1, Z.-L. Gao1.
1The Third Afﬁliated Hospital of Sun Yat-sen University,
China
Objective: To investigate the clinical outcome and effect
of interferon treatment on chronic hepatitis patients.
Methods: 99 cases of hepatitis C patients were follow-up by
method of retrospective survey combined with prospective
study.
Results: 99 cases of patients were infected with HCV virus
mainly through blood and blood products transfusion. They
were diagnosed mainly from 2000 to 2005. 10 cases (12.12%)
developed HCV-related cirrhosis or liver carcinoma in ﬁve
years. Of 42 cases of patients who once treated with
interferon, 36 cases (85.71%) relapsed and most of them
were old man with long-standing course and nonstandard
application of interferon and ribavirin. 27 cases of relapsed
(75%) were administrated with interferon once again with
ideal effect. The incidence of cirrhosis and liver cancer of
non-treatment, six months interferon treatment, more than
six months interferon treatment were 26.92%, 10%, 6.35%
respectively (P= 0.028).
Conclusion: Hepatitis C virus infection increases the risk
of liver cirrhosis and liver cancer. Interferon therapy could
effectively control the virus and improve outcomes.
PP-129 Incidence of acquiring hepatitis B and C virus
infection in hemodialysis patients
B. Fekrey1, N. Allam1 *, A. Abas1, S. Mahmood1, I. Waked1.
1National Liver Institute, Egypt
Objective: To study incidence of acquiring hepatitis B
(HBV) and C (HCV) in hemodialysis with and without blood
transfusion to decide whether dialysis per se is a risk.
Methods: 90 patients starting hemodialysis were followed
up for six months. They were divided into: group I didnot
receive blood transfusion; group II did. HbsAg, anti-HBc
and anti-HCV Abs were performed at the start and six
months later. Group I was subdivided into: Subgroup Ia:
no evidence of HBV or HCV infection. Subgroup Ib: HBV-
infected. Subgroup Ic: negative for HbsAg, anti-HBc but
anti-HCV positive. Group II: all negative. Patients were
distributed in four units with peculiar protective strategies.
Unit A isolates infected patients in separate room and on
dedicated machines. Unit B devotes machines for HBV and
HCV infected patients. Unit C does not isolate HCV patients
and does not accept HBV patients. Unit D accepts HBV
patients with or without HCV in a common ward and on
common machines.
Results: In group I, no cases acquired HBV infection; in the
second, 4.4% acquired HB surface antigenemia. Attributable
risk due to blood transfusion was 4.4. These two cases
occurred in unit C. Regarding HCV infection, incidence was
23.3% in group I versus 20% in group II. Relative risk due to
blood transfusion was 0.86 versus 1.16 due to hemodialysis
per se. Units isolating HCV patients or using dedicated
machines had signiﬁcantly lower rates. In unit A and B,
incidence was 15.16% and 13.3% respectively versus 41.66%
and 26.6% in unit C and D respectively.
Conclusion: HCV de novo infection is relatively high
among hemodialysed patients and is not related to blood
transfusion. CDC guidelines recommend isolation of HBV
patients in separate rooms. We strongly suggest strict
preventive measures in addition to isolation of HCV patients,
a policy that needs further evaluation.
PP-130 Serum HDL and Vitamin D levels are strongly
associated with SVR in chronic hepatitis C naïve
genotype-1 patients
M. Grosovski1 *, G. Morad2, W. Nseir3, N. Assy2,4. 1Ort
Braude College, Biotechnology, Karmiel, Israel, 22 Liver
Unit, Ziv Medical Centre, Safed, Israel, 3Internal Medicine,
Holy Family Hospital, Nazareth, Israel, 4Faculty of
Medicine, Technion, Israel
Background: HCV is a multi-step process, involving several
viral and cellular factors that trigger virus uptake into the
hepatocyte.
Aim: To assess the association between serum lipoproteins
and vitamin D levels and sustained viral response (SVR).
Methods: 80 chronic HCV genotype 1 naïve patients received
peg interferon alpha-2a (sc 180 mg once weekly) or peg
interferon alpha 2b (1.5mg/kg) plus ribavirin 1200mg/d
during 48 weeks. HCV RNA was assessed by RT-PCR and
undetectable HCV RNA at week 24 post treatment was
considered as SVR. Patients were divided into two groups
(responders vs non-responders according to SVR).
Results: The patients had a high BMI (28±2), high
viral load (>400,000 IU/l) and high ﬁbrosis score (Metavir
scores F2) in 50%, 40%, and 30% respectively. Responders
(42% of patients) had lower serum cholesterol, HDL,
LDL levels (P= 0.01, P= 0.008, P= 0.009 respectively), and
higher vitamin D levels (P< 0.001) than non-responders.
Multivariate logistic regression analysis showed that gender
(P< 0.001), low cholesterol, HDL levels (P< 0.03, P< 0.001),
